CancerConnect News: The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a […]
The US Food and Drug Administration (FDA) today approved the oral therapy Xermelo (telotristat ethyl) to be used in combination […]
Sun Valley ID & Austin TX— OMNI Health Media (OMNI) announces the launch of a new online community on CancerConnect […]
New Drug Shows Improved Outcomes for Patients with Advanced Metastatic Mid-gut Neuroendocrine Tumors
A new therapy in development for the treatment of mid-gut neuroendocrine tumors, a rare type of cancer that occurs in […]
The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors […]
The US Food and Drug Administration has approved the targeted drug Sutent® (sunitinib) for the treatment pancreatic neuroendocrine tumors (PNET). […]
The US Food and Drug Administration has approved Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors (PNET). Pancreatic […]
In two separate Phase III clinical trials, the targeted drugs Sutent® (sunitinib) and Afinitor® (everolimus) delayed the progression of advanced […]
In a recent Phase III trial, the targeted therapy Afinitor® (everolimus) more than doubled progression-free survival time among patients with […]
The combination of Afinitor® (everolimus) and Temodar® (temozolomide) appears to be active against advanced pancreatic neuroendocrine tumors. The details of this Phase I/II study were presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
Among patients with advanced pancreatic neuroendocrine tumors (a cancer that develops in the hormone-producing area of the pancreas), treatment with the targeted therapy Sutent® (sunitinib) more than doubled progression-free survival compared with placebo. These results were presented at the 2010 ASCO Gastrointestinal Cancers Symposium.
Among patients with advanced neuroendocrine tumors of the midgut, treatment with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) appears to significantly delay cancer progression. The results of this Phase III clinical trial were published in the Journal of Clinical Oncology.
Delcath Systems, Inc. has received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the use […]